Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics Inc (ALGS) is a clinical-stage biopharmaceutical company developing novel treatments for chronic hepatitis B and liver diseases. The company's news flow typically centers on clinical trial updates, regulatory milestones, research presentations at medical conferences, and drug development progress announcements.
Investors and researchers tracking Aligos Therapeutics can expect updates on multiple fronts. Clinical trial progress represents the most material news category for the company, as advancement through trial phases and data readouts directly impact development timelines and commercial potential. Regulatory communications, including approvals to begin new trials or designations from health authorities, provide insight into the company's path toward potential drug approval.
The company frequently presents preclinical and clinical data at hepatology and infectious disease conferences, offering visibility into drug candidate performance and scientific validation. Corporate developments such as research partnerships, licensing agreements, or strategic collaborations can signal important shifts in development strategy or provide non-dilutive funding. Leadership appointments and inducement grants, while less directly tied to drug progress, reflect the company's organizational evolution and talent acquisition.
For those following hepatitis B drug development or the broader antiviral therapeutics space, Aligos Therapeutics' news provides insight into multiple therapeutic modalities progressing through clinical evaluation. The company's multi-platform approach means developments can emerge across different drug classes and mechanisms of action.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced the appointment of James Scopa, J.D., MBA, to its board of directors on April 27, 2021. CEO Lawrence Blatt stated this addition supports Aligos' growth as it transitions towards mid-stage clinical trials for chronic hepatitis B. Scopa brings over 30 years of life sciences experience as an investor and advisor, positioning him to provide strategic guidance. He has previously held significant roles at MPM Capital and Deutsche Banc Alex. Brown, enhancing Aligos' leadership as it expands in viral and liver disease therapies.
Aligos Therapeutics has commenced patient dosing in its ongoing study of ALG-000184, a drug candidate targeting chronic hepatitis B (CHB). This study evaluates ALG-000184's ability to inhibit viral replication by measuring HBV DNA and RNA levels. The company aims to combine ALG-000184 with other therapies to achieve better treatment outcomes. Preliminary data from previous trials indicate a favorable safety profile. Initial data on safety and antiviral activity are expected in the second half of 2021, contributing to Aligos' goal of improving CHB treatment regimens.
Aligos Therapeutics (NASDAQ: ALGS) reported strong financial results for Q4 and the full year 2020, with cash reserves of $243.5 million following a successful IPO raising $167.2 million. The company advanced two drug candidates, ALG-010133 and ALG-000184, into clinical trials for Chronic Hepatitis B (CHB) and expects to generate safety and antiviral activity data in 2021. However, net losses reached $108.5 million for the year, up from $52.3 million in 2019, reflecting increased R&D expenses of $79.9 million.
Aligos Therapeutics (Nasdaq: ALGS) has initiated dosing of its first drug candidate, ALG-010133, in chronic hepatitis B (CHB) patients as part of the ALG-010133-101 study. This proprietary molecule aims to reduce viral S-antigen levels, pivotal for HBV replication. Preclinical studies show promising inhibition of S-antigen. Currently, 72 healthy volunteers have been dosed, indicating an acceptable safety profile. Results from the initial patient cohorts are expected in the second half of 2021. Aligos aims to develop a treatment regimen that may lead to a functional cure for CHB.
Aligos Therapeutics (Nasdaq: ALGS) announced the presentation of its SARS-CoV-2 3CLpro inhibitor candidate, ALG-097111, at the 28th Conference on Retroviruses and Opportunistic Infections. The presentation highlighted in vivo evidence of potent virus inhibition in infected hamsters, achieving a 3.5 log10 reduction in viral RNA. ALG-097111 showed high selectivity with an IC50 of 7 nM, indicating its potential as a targeted therapeutic option amid COVID-19's evolving strains. CEO Lawrence Blatt emphasized its importance for untreated and vaccine-resistant patients.
Aligos Therapeutics (Nasdaq: ALGS) will present four posters at the 30th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL) from February 4-6, 2021. The presentations will showcase progress in their chronic hepatitis B (CHB) drug candidates, ALG-010133 and ALG-000184, currently in Phase 1a/b studies. Notable findings include ALG-010133's promising preclinical efficacy and pharmacokinetics, and ALG-000184's safety and tolerability data. These trials aim to develop effective combination therapies against CHB.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced that CEO Lawrence Blatt will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 3:40 PM ET. The presentation will include a virtual Q&A session, with the webcast recording available for 30 days afterward. Aligos focuses on developing novel therapeutics for viral infections and liver diseases, particularly targeting chronic hepatitis B and nonalcoholic steatohepatitis. Founded in 2018, the company aims to lead in antiviral therapies using its extensive drug development expertise.
Aligos Therapeutics (Nasdaq: ALGS) recently presented at the RespiDART & Emerging Viruses 2020 meeting, showcasing advancements in their SARS-CoV-2 therapeutic candidate, ALG-097111. The presentation underscored the development of a multiplex screening platform to identify selective inhibitors for the viral 3CLpro protease, essential for viral replication. ALG-097111 demonstrated significant inhibition without affecting human cathepsin L, highlighting its potential as a targeted treatment for SARS-CoV-2. Collaborations with KU Leuven were pivotal in these developments.
Aligos Therapeutics (Nasdaq: ALGS) announced a collaboration with Merck to leverage its oligonucleotide platform technology for developing therapies targeting non-alcoholic steatohepatitis (NASH) and potentially other conditions. The agreement includes an upfront payment and up to $458M in development milestones along with tiered royalties on sales. Aligos will focus on designing and optimizing oligonucleotides, while Merck will handle clinical development and commercialization. This collaboration aims to address the critical need for effective NASH treatments amidst growing liver disease concerns.
Aligos Therapeutics (Nasdaq: ALGS) presented six posters and one oral presentation at the AASLD Liver Meeting Digital Experience 2020, highlighting advancements in its liver disease programs. Key updates included progress on chronic hepatitis B (CHB) therapies and the nonalcoholic steatohepatitis (NASH) treatment candidate ALG-055009. The company is optimistic about its combination regimens for CHB that may lead to functional cures and has begun Phase 1 trials for two drug candidates, ALG-010133 and ALG-000184, aimed at CHB.
FAQ
What is the current stock price of Aligos Therapeutics (ALGS)?
What is the market cap of Aligos Therapeutics (ALGS)?
